Artificial Intelligence | April 8–10, 2019 | Boston, MA USA

Vicki Seyfert-Margolis, PhD

  • CEO, My Own Med Inc.,

Vicki Seyfert-Margolis, Ph.D. founded My Own Med in January 2013, based on over two years of work on a
database, web and mobile application platform technology for family-based co-management of health. She has
extensive experience from efficacy to effectiveness to clinical trial designs that incorporate digital technology into
RWE. Her recent publication in Nature Biotechnology (The Evidence Gap; Vol36 No.3, March 2018) outlines her
experience and views on these subjects. Previously, Dr. Seyfert-Margolis was the Senior Advisor for Science
Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science. Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of
researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the
development of over 20 leading edge assay development and centralized laboratory facilities, bringing them to GLP
and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation. Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs. Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania’s School of Medicine, and her post-doctoral fellowship work at Harvard University and the National Cancer Institute

This speaker appears at this event: